Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 465 of 6351
-
New hope for lung cancer: experimental drug RC148 takes on standard therapy
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Part…
Phase 3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Tiny particles packed with steroids could restore hearing
Disease control Recruiting nowPrimary Objective To compare the efficacy of a single course of IT Exo-Dex versus conventional IT dexamethasone and exosome vehicle alone, as measured by the mean change in pure-tone average (PTA; 0.5, 1, 2, 4 kHz) from baseline to the 4-week post-treatment endpoint. Secondary O…
Sponsor: Kafrelsheikh University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New chemo cocktail aims to shrink pancreatic tumors
Disease control Recruiting nowThis is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal adenocarcinoma (PDAC).
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a common antibiotic help the brain heal after a stroke?
Disease control Recruiting nowThis is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. It aims to evaluate the efficacy and safety of oral minocycline in patients with acute spontaneous intracerebral hemorrhage within 48 hours of onset.
Phase 3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New RNA drug shows promise in preventing HAE attacks in ongoing study
Disease control Recruiting nowStudy ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The…
Phase 3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New PTSD drug shows promise in Large-Scale trial
Symptom relief Recruiting nowThis study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, par…
Phase 3 • Sponsor: Transcend Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New Light-Activated gel could save diabetic feet from amputation
Disease control Recruiting nowProtocol No. CHLORIN E6-IIB/III-01/Protocol/1.1 Title:Single-Centre, open-labeled, randomized, Phase IIb and Phase III clinical studies to evaluate the safety, tolerability, and efficacy of Chlorin E6 (Gel Formation) as a photosensitizing agent for the management of Diabetic Foot…
Phase 3 • Sponsor: United Medical and Dental College • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control Not yet recruitingThis phase II trial tests how well giving Y-90 radioembolization, durvalumab, tremelimumab and zanzalintinib works for the treatment of hepatocellular carcinoma that cannot be removed by surgery (unresectable) and that has spread to nearby tissue or lymph nodes (locally advanced)…
Phase 2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail shows promise for rare sarcoma
Disease control Recruiting nowThis is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating …
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Stroke drug trial aims to boost brain recovery after clot removal
Disease control Not yet recruitingThe goal of this clinical trial is to learn if immediate intra-arterial tirofiban after complete recanalization can improve recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. It will also learn about the safety of this treatment. …
Phase 3 • Sponsor: Shandong Provincial Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to tame rare artery disease
Disease control Not yet recruitingThis is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.
Phase 4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New immune combo aims to fight lymphoma without chemo
Disease control Not yet recruitingOpen-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Timing is everything: new trial aims to save lives from immune storm
Disease control Not yet recruitingHemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by hyperactivation of the immune system, leading to a cytokine storm responsible for organ failures. Consequently, patients with HLH often require intensive care management, where their short-te…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Starving liver tumors: new combo aims to stop cancer from eating itself
Disease control Recruiting nowTrans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemot…
Phase 1/2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can blood transfusions protect pregnant women with sickle cell disease?
Disease control Recruiting nowThe goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations…
Phase 4 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for STK11 lung cancer: experimental combo enters trial
Disease control Recruiting nowThis phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has s…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Clot-Busting heart procedure put to the test in massive new trial
Disease control Not yet recruitingThe goal of this clinical trial is to learn if adding standardized manual thrombus aspiration to primary percutaneous coronary intervention (PPCI) works better to improve heart health outcomes and protect long-term heart function in adults with acute ST-segment elevation myocardi…
Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to make inoperable liver cancer removable
Disease control Recruiting nowHepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii. This disparity is influenced by factors such as hi…
Phase 1 • Sponsor: University of Hawaii • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo therapy offers hope for patients with inoperable liver cancer
Disease control Recruiting nowThis study is a single-arm prospective clinical trial that enrolled 94 patients with unresectable hepatocellular carcinoma(HCC) who received first-line treatment with tislelizumab combined with Huaier granule. By comparing the objective response rate (ORR) and other data with tho…
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Engineered immune cells take on tough blood disorder
Disease control Recruiting nowThis is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy
Early phase 1 • Sponsor: The Second Hospital of Anhui Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC